Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hemagglutinin (HA) protein of the influenza A virus H1 subtype is a trimeric glycoprotein essential for viral entry into host cells. It mediates receptor binding via the globular head (primarily HA1) and membrane fusion via conformational changes (primarily HA2). The major antigenic sites Sa, Sb, Ca1/Ca2, and Cb are located on the HA1 subunit and are primary targets for neutralizing antibodies. Mutations within these sites (antigenic drift) allow the virus to evade pre-existing immunity. Sa and Sb are strain-specific while Ca/Cb may be more conserved.
Neutralizing antibodies bind to antigenic sites (Sa, Sb, Ca, Cb), blocking virus attachment or membrane fusion. HA inhibitors block membrane fusion.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A Virus Hemagglutinin H1 Subtype Antigenic Sites Sa, Sb, Ca, Cb (H1 HA Sa/Sb/Ca/Cb).